ClinicalTrials.gg
Active, not recruitingNCT06356571SubQSAUpdated Oct 26, 2026

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 2 interventional study of Isatuximab SC-OBDS and Montelukast in Plasma Cell Myeloma Refractory, sponsored by Sanofi. Active, not recruiting at 34 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Planned enrollment
122nd of 373
64 · median 45
Started
2025
with 9 others
Phase 2
217 of 381
18 open now
Primary completion
2027-04
later than 54 of 103 live
Registered
360th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 122nd largest by planned enrollment of the 373 interventional ones that give a count, is one of 10 that started in 2025, is one of 217 in phase 2, reaches primary completion later than 54 of the 103 other live ones, and was the 360th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

Read the detailed description

The duration of the study for a participant will include a period for screening of up to 28 days, a study treatment period of 12 months (except early discontinuation), the end-of-treatment (EOT) visit about 30 days after the last dose of study treatment, and a study follow-up period until death or the final study cut-off date. A cycle duration is 28 days. After study treatment discontinuation, participants will return to the study site 30 days after the last dose of study treatment for the EOT visit or before further anti-myeloma therapy initiation, whichever comes first.

03

Conditions studied

  • Plasma Cell Myeloma Refractory

Browse trials for

Keywords

  • Anti CD38 monoclonal antibody
  • SARCLISA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a documented diagnosis of MM.
  • Participants with defined as at least one of the following:

    • Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants with MM with at least 1 and no more than 3 prior lines of therapy.
  • use by [men and women] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    • Male participants agree to practice true abstinence or agree to use contraception while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.
    • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of (FCBP XE " FCBP " \f Abbreviation \t "female of childbearing potential" ) or agrees to practice complete abstinence or use contraception.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Primary MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course.
  • Participants with prior anti-CD38 treatment if: a) administered \< 6 months before first isatuximab administration or, b) intolerant to the anti-CD38 previously received.
  • Participants who are refractory to carfilzomib.
  • Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or ) of study treatment that are not amenable to premedication with , or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents.
  • Participants with to dexamethasone and/or to carfilzomib.
  • Any anti-myeloma drug treatment within 14 days before the first isatuximab administration, including dexamethasone.
  • Prior allogenic HSC transplant with active (GvHD XE " GvHD " \f Abbreviation \t "graft versus host disease" ) (GvHD any grade and/or being under treatment within the last 2 months).
  • Any major procedure within 14 days before the first isatuximab administration: plasmapheresis, major surgery (kyphoplasty is not considered a major procedure), radiotherapy.
  • Vaccination with a within 4 weeks before the first isatuximab administration. Seasonal flu vaccines that do not contain live virus are permitted.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Isatuximab in combination with weekly carfilzomib and dexamethasone

    Participants will receive isatuximab via SC-OBDS administration in combination with weekly carfilzomib and dexamethasone. Isatuximab will be administered on days 1, 8, 15 and 22 for Cycle 1 and then on days 1, 15 for subsequent cycles. Carfilzomib will be administered intravenously (IV) at a starting dose on Day 1 of Cycle 1 and then escalated dose on Days 8 and 15 of Cycle 1, followed by Days 1, 8 and 15 of subsequent cycles. Dexamethasone will be given on Days 1, 8, 15, and 22 of Cycle 1 and then on Days 1, 8 and 15 of subsequent cycles. Dexamethasone will be administered IV on Cycle 1 Day 1, and IV or PO in the subsequent administrations. 1 cycle = 28 days.

    Drug: Isatuximab SC-OBDS · Drug: Montelukast · Drug: Dexamethasone · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone · Drug: Carfilzomib

Interventions

  • Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS

    Also known as: SAR650984, Sarclisa

  • Pharmaceutical form:As per local commercial product-Route of administration:Oral

  • Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV

  • Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV

  • Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)

  • Pharmaceutical form:As per local commercial product-Route of administration:IV

  • Pharmaceutical form:As per local commercial product-Route of administration:IV

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR), according to IMWG criteria assessed by investigator.

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 32 months

Secondary outcomes

  1. Number of participants with infusion reactions (IRs)

    Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 38 months

  2. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities (per NCI-CTCAE grade or PCSA if NCI-CTCAE scale is not applicable)

    Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 38 months

  3. Number of participants with injection site reactions (ISRs)

    Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 38 months

  4. CR or better

    CR or better assessed according to International Myeloma Working Group (IMWG) criteria assessed by investigator. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow aspirates, and a normal FLC ratio of 0.26-1.65 is required for FLC disease only. Two consecutive assessments are needed. No known evidence of progressive disease or new bone/soft tissue lesions if radiographic studies were performed.

    Time frame: 12 months after the Last Participant In (LPI) i.e., approximately 38 months

  5. VGPR or better

    VGPR or better assessed according to IMWG criteria assessed by investigator. VGPR is defined as Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 h, or ≥90% decrease in the sum of maximal perpendicular diameter compared to baseline in soft tissue plasmacytoma. FLC only: a ≥90% decrease in the difference between involved and uninvolved FLC levels. Two consecutive assessments are needed. No known evidence of progressive disease or new bone/soft tissue lesions if radiographic studies were performed.

    Time frame: 12 months after the Last Participant In (LPI) i.e., approximately 38 months

  6. Duration of response (DOR)

    DOR, defined as the time from date of first investigator determined response for achieving PR or better to first documentation of progressive disease (PD) determined by investigator or death, whichever occurred first.

    Time frame: 12 months after the Last Participant In (LPI) i.e., approximately 38 months

  7. Time to first response (TT1R)

    TT1R, defined as the time from first isatuximab administration to first investigator-determined response (PR or better) that is subsequently confirmed.

    Time frame: 12 months after the Last Participant In (LPI) i.e., approximately 38 months

  8. Time to best response (TTBR)

    TTBR, defined as the time from first isatuximab administration to first occurrence of investigator-determined best response (PR or better) that is subsequently confirmed.

    Time frame: 12 months after the Last Participant In (LPI) i.e., approximately 38 months

  9. Patient experience and Satisfaction Questionnaire v2 (PESQ v2)

    The PESQ v2 has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects and recommendation) and the administration method (comfortability, pain, side effects and overall satisfaction). This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The trial specific version of the PESQ v2 contains of items administered for the duration of treatment. Response options are presented as a 5-point Likert scale ranging from Strongly agree/very satisfied/definitely yes to strongly disagree/very dissatisfied/definitely no.

    Time frame: Cycle 3/Day 15 and Cycle 6/Day 15

  10. Positivity titer of anti-drug antibodies (ADA) in a subset of approximately 30 participants

    Blood samples will be collected for assessing the presence of ADA against isatuximab in plasma from approximately 30 participants. Plasma samples will be screened for antibodies binding to isatuximab and the titer of confirmed positive samples will be reported.

    Time frame: From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e, approximately up to 15 months (1 cycle = 28 days)

  11. Maximum observed concentration (Cmax) of isatuximab in a subset of approximately 30 participants

    Time frame: Multiple timepoints in Cycle 1 (1 cycle = 28 days)

  12. Cumulative area under the curve over the first 4 weeks of isatuximab treatment (AUC4 weeks) in a subset of approximately 30 participants

    Time frame: Multiple timepoints in Cycle 1 (1 cycle = 28 days)

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Apr 2027, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
Apr 10, 2024
StartActual
Mar 17, 2025
Primary completionEst.
Apr 1, 2027was Jan 2027
CompletionEst.
Jul 15, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Maryland Oncology Hematology - Bethesda- Site Number : 8400038 · Bethesda, United States
  • AMR Clinical Kansas City, Missouri- Site Number : 8400056 · Kansas City, United States
Show 2 removed
  • Maryland Oncology Hematology- Site Number : 8400038 · Washington D.C., United States
  • Alliance for Multispeciality Research - Kansas City- Site Number : 8400056 · Kansas City, United States
Oct 26, 2026
Primary completion
Jan 8, 2027→Apr 1, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Maryland Oncology Hematology - Bethesda- Site Number : 8400038 · Bethesda, United States
    • AMR Clinical Kansas City, Missouri- Site Number : 8400056 · Kansas City, United States
    Show 2 removed
    • Maryland Oncology Hematology- Site Number : 8400038 · Washington D.C., United States
    • Alliance for Multispeciality Research - Kansas City- Site Number : 8400056 · Kansas City, United States
    Primary completion Jan 8, 2027→Apr 1, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06356571
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Mar 17, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Carfilzomib

Start the discussion